Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
CYP4F2 8529 CHEMBL182310 CHEMBL182310 inhibitor GuideToPharmacologyInteractions
CYP4F2 8529 ACENOCOUMAROL CHEMBL397420 PharmGKB
CYP4F2 8529 PHENPROCOUMON CHEMBL16694 PharmGKB

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
CYP4F2 CYP4F2*3 *3 warfarin dosage not stated This study assessed whether a pharmacogenetic algorithm, which included this variant as well as the VKORC1 rs9923231, CYP2C9*2 and CYP2C9*3 variants, is superior in overall anticoagulation control when compared to clinical standard of care. CYP4F2 *3 is associated with dose of warfarin. 26710337 1448276515
CYP4F2 rs2108622 T warfarin "dosage","metabolism/PK" not stated in a dosing algorithm to predict warfarin dosage (included age, BMI, thyroid status, CYP2C9; *2 (rs1799853), *3 (rs1057910), *8 (rs75838422) VKORC1; *3 (rs7294),*4 (rs17708472), -1639G>A (rs9923231), CYP4F2; V433M (rs2108622), GGCX; G8016A (rs699664). Allele T is associated with dose of warfarin. 22676192 978614465
CYP4F2 rs2108622 CC warfarin dosage yes Patients with the CC genotype had a significantly lower dose of warfarin (3.0+/-1.5 mg/day) as compared to those with the TT genotype (3.5+/-2.5 mg/day). Additionally, this variant was included in an algorithm for determining warfarin dose. Genotype CC is associated with decreased dose of warfarin as compared to genotype TT. 21326313 1448275984
CYP4F2 rs2108622 TT warfarin dosage yes Average mean stable warfarin dose was 5.48+/-1.90 mg/day. Current age, age at operation, atrial fibrillation were all significantly associated with warfarin dose. Please note, alleles have been complimented to the + strand. Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT. 26257249 1446765933
CYP4F2 rs2108622 T warfarin dosage no in Alaska Native and American Indian People. Allele T is not associated with dose of warfarin as compared to allele C. 30821933 1450370810
CYP4F2 rs2108622 T warfarin "dosage","efficacy" no A model was created to predict maintenance doses for children of different ages, all with a baseline INR of 1 and a target INR of 2.5, based on longitudinal data from children taking warfarin. Though there was a trend for a higher dose per T allele, CYP4F2 genotype was not retained in the final model. CYP2C9 genotype, VKORC1 genotype, bodyweight, age, baseline INR, target INR and time since initiation of therapy were all found to be significant causes of warfarin dose variability in children. Allele T is not associated with increased dose of warfarin in children with Heart Diseases as compared to allele C. 24330000 1184654456
CYP4F2 rs2108622 CT + TT acenocoumarol dosage yes The meta-analysis showed that this variant (CYP4F2*3) was consistently associated with an increase in mean coumarin dose (+9% (95%CI 7-10%), with a higher effect in females, in patients taking acenocoumarol and in Whites and Asians, but with a low effect size and not in Blacks or other ethnic groups. Genotypes CT + TT are associated with increased dose of acenocoumarol or warfarin as compared to genotype CC. 30506689 1450186421
CYP4F2 rs2108622 TT warfarin dosage yes in Korean patients with mechanical cardiac valves. Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT. 22549502 1184510039
CYP4F2 rs2108622 CT + TT warfarin dosage no Genotypes CT + TT is not associated with dose of warfarin in children as compared to genotype CC. 27262824 1448108296
CYP4F2 rs2108622 TT phenprocoumon dosage yes A gene dose effect was seen in that an increasing number of variant alleles resulted in an increased stable dose of phenprocoumon. Genotype TT is associated with increased dose of phenprocoumon as compared to genotypes CC + CT. 23510058 982015200
CYP4F2 rs2108622 T warfarin dosage not stated Allele T is associated with dose of warfarin as compared to allele C. 28973620 1449269209
CYP4F2 rs2108622 CT + TT warfarin dosage yes in European americans, but not African americans. Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC. 26877068 1447952609
CYP4F2 rs2108622 T warfarin dosage yes MWWD (Mean weekly warfarin dose): CC 20.54 mg/wk;CT: 24.19 mg/wk;TT:38.44 mg/wk. About 7% of mean weekly warfarin dose variance is explained by the genotype at this SNP. Allele T is associated with increased dose of warfarin as compared to allele C. 19207028 1183700033
CYP4F2 rs2108622 CC warfarin metabolism/PK no Genotype CC is not associated with dose of warfarin in children as compared to genotype TT. 22130800 982047993
CYP4F2 rs2108622 CT warfarin dosage yes Genotype CT is associated with increased dose of warfarin as compared to genotype CC. 22172097 1184510155
CYP4F2 rs2108622 C warfarin dosage no A weak association was found but it did not reach significance: "In addition, a relationship was found between the CYP4F2 (rs2108622) genotype and warfarin maintenance dose, but it was much weaker than those described earlier. Patients with the wild-type CYP4F2 (rs2108622) sequence (CC) required a mean dose of 2.8 ± 1.5 mg, whereas heterozygotes (CT) and homozygotes (TT) were found to require higher doses (3.0 ± 1.5 mg (+7%) and 3.3 ± 1.7 mg (+18%), respectively; P = 0.13)." Allele C is associated with dose of warfarin. 19794411 608431751
CYP4F2 rs2108622 CC warfarin dosage yes 4% to 12% increase in the warfarin dose per T allele. This is in Whites presumably of European descent. Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT. 18250228 699638607
CYP4F2 rs2108622 TT warfarin dosage yes Genotype TT is associated with increased dose of warfarin as compared to genotype CC. 23104259 1184483813
CYP4F2 rs2108622 CC warfarin dosage yes Genotype CC is associated with decreased dose of warfarin as compared to genotype CT. 20442691 769246303
CYP4F2 rs2108622 CT + TT warfarin dosage yes Patients had a stable therapeutic international normalized ratio (INR) between 2 and 3. Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC. 21383771 769182565
CYP4F2 rs2108622 CT + TT warfarin dosage yes in Han-Chinese patients with mechanical heart valve replacement. Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC. 23949431 1184482772
CYP4F2 rs2108622 T warfarin dosage yes Allele T is associated with increased dose of warfarin as compared to allele C. 19300499 827641885
CYP4F2 CYP4F2*1, CYP4F2*3 *3/*3 warfarin dosage yes Genotyped for rs2108622. [stat_test: kruskal-wallis] CYP4F2 *3/*3 is associated with increased dose of warfarin in people with a stable international normalized ratio of between two and three as compared to CYP4F2 *1/*1. 21174619 827783872
CYP4F2 rs2108622 CT + TT warfarin dosage yes Genotypes CT + TT are associated with increased dose of warfarin in people with Thromboembolism as compared to genotype CC. 22528326 827925134
CYP4F2 rs2108622 C warfarin dosage yes Allele C is not associated with increased dose of warfarin in people with warfarin maintenance treatment as compared to allele T. 22871975 981239905
CYP4F2 rs2108622 TT warfarin dosage yes The authors report that rs21086622 genotype accounted for 1.9% of the variability in warfarin dose. Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT. 24019055 1183704839
CYP4F2 rs2108622 T phenprocoumon dosage yes Each additional CYP4F2 variant allele increased phenprocoumon maintenance dosage 1.5 mg/week (P=0.022).The study found additive effects of the variant alleles of CYP2C9 (rs4086116) and CYP4F2 (rsrs2108622) on VKORC1. Allele T is associated with increased dose of phenprocoumon maintenance dosage by 1.5 mg/week as compared to allele C. 21063236 827807881
CYP4F2 rs2108622 C warfarin no A significant association between genotype and dose was not found in this study; however, the trend for this association "was consistent with the literature". Allele C is not associated with decreased dose of warfarin as compared to allele T. 21228733 827864558
CYP4F2 rs2108622 TT acenocoumarol dosage no Patients with the TT genotype did not require significantly different weekly maintenance doses of acenocoumarol compared to CC homozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. Genotype TT is not associated with dose of acenocoumarol as compared to genotype CC. 22486182 982010056
CYP4F2 rs2108622 CT + TT warfarin "dosage","efficacy" yes 3.2 mg/day vs. 2.9 mg/day. There were only 15 TT patients. Genotypes CT + TT are associated with increased dose of warfarin in people with mechanical heart valve replacement as compared to genotype CC. 20653676 981483967
CYP4F2 rs2108622 C warfarin "dosage","efficacy" no This SNP showed a weak but not significant association with dosage when analyzed alone, and when analyzed with CYP2C9*2,CYP2C9*3 and VKORC1*2, also provided no significant contribution. Allele C is not associated with dose of warfarin in people with Myocardial Infarction as compared to allele T. 21127708 981500599
CYP4F2 rs2108622 T warfarin "dosage","efficacy" yes This was a replication cohort. Results were first stratified by rs10509680 (CYP2C9) and rs9923231 (VKORC1) genotypes. Allele T is associated with increased dose of warfarin as compared to allele C. 20833655 981481830
CYP4F2 rs2108622 T warfarin "dosage","efficacy" yes The association was not significant in a GWAS comparing high and low-dose warfarin requirers, but was significant after results were first stratified by rs10509680 (CYP2C9) and rs9923231 (VKORC1) genotypes. Allele T is associated with increased dose of warfarin as compared to allele C. 20833655 981481812
CYP4F2 rs2108622 CC + CT warfarin dosage yes Analysis was performed on stable warfarin dose. Alleles give was reverse strand A and G. Genotypes CC + CT are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT. 26223945 1448431513
CYP4F2 rs2108622 CC warfarin dosage yes Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT. 23061746 981754851
CYP4F2 rs2108622 CC acenocoumarol dosage no No significant difference was seen between the daily dose for CYP4F2 wildtype patients and the daily dose for CYP4F2 variant carriers. This study provides an algorithm for predicting the maintenance dose of acenocoumarol using genotypes as well as clinical factors as predictive variables. Genotype CC is not associated with decreased dose of acenocoumarol as compared to genotypes CT + TT. 22629463 981954447
CYP4F2 rs2108622 CT acenocoumarol dosage no Patients with the CT genotype did not require significantly different weekly maintenance doses of acenocoumarol compared to CC homozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. Genotype CT is not associated with dose of acenocoumarol as compared to genotype CC. 22486182 982010069
CYP4F2 rs2108622 TT acenocoumarol dosage no While a trend towards increased dose of acenocoumarol with increasing numbers of variant alleles was seen, it was not statistically significant. Genotype TT is not associated with increased dose of acenocoumarol as compared to genotypes CC + CT. 23510058 982015210
CYP4F2 rs2108622 TT acenocoumarol dosage yes Patients with the TT genotype required significantly higher weekly maintenance doses of acenocoumarol compared to CT heterozygotes. Maintenance doses were measured over at least a 3 month period during which stable anticoagulation had been achieved. Patients were treated with acenocoumarol for various unspecified indications. Genotype TT is associated with increased dose of acenocoumarol as compared to genotype CT. 22486182 982010017
CYP4F2 rs2108622 CC phenprocoumon "dosage","metabolism/PK" yes Daily dose of phenprocoumon is not significantly associated with this SNP. Daily dose is negatively correlated with age. This study published an algorithm for daily dose that includes height, although height was not significant in univariate analysis. This SNP is also not significantly associated with phenprocoumon concentration. Genotype CC is not associated with increased dose of phenprocoumon as compared to genotypes CT + TT. 21110013 982046672
CYP4F2 rs2108622 T warfarin dosage no Allele T is not associated with decreased dose of warfarin as compared to allele C. 20072124 982037942
CYP4F2 rs2108622 CC warfarin efficacy yes Patients in this study were treated with low dose (1-2mg/day) warfarin. No association was found between this SNP and response to warfarin (metabolism or prothrombin time (INR)). Genotype CC is not associated with response to warfarin as compared to genotypes CT + TT. 22855348 1183690117
CYP4F2 rs2108622 C warfarin dosage yes The study purpose was to develop a model for stable maintenance warfarin dose prediction. Most patients had a history of venous thromboembolism. CC patients required a slightly lower dose than CT patients, who required a lower dose than TT patients. Allele C is associated with decreased dose of warfarin in people with venous thromboembolism as compared to allele T. 20421126 1183701528
CYP4F2 rs2108622 T warfarin dosage yes TT > CT > CC. Allele T is associated with increased dose of warfarin as compared to allele C. 19297519 1183700228
CYP4F2 rs2108622 CC + CT warfarin dosage yes This SNP was presented as CYP4F2 1297G>A. Patients with the TT allele showed significantly higher doses of warfarin as compared to patients carrying the wildtype allele, C. However, this effect was small as the difference in dose between wildtype (CC) and homozygous variant (TT) genotypes was 0.6 mg/day. Genotypes CC + CT is associated with decreased dose of warfarin in people with Cardiovascular Diseases as compared to genotype TT. 23990957 1183697697
CYP4F2 rs2108622 T vitamin e efficacy no The T allele is not significantly associated with improvement in liver histology in pediatric or adult patients receiving vitamin E (alpha-tocopherol) supplements at week 48 or at week 96. Allele T is not associated with response to vitamin e in people with hepatic steatosis as compared to allele C. 24759732 1184472059
CYP4F2 rs2108622 CT + TT warfarin dosage yes Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC. 25042728 1184511577
CYP4F2 rs2108622 CT + TT acenocoumarol dosage yes Genotypes CT + TT is associated with increased dose of acenocoumarol as compared to genotype CC. 25042728 1184511581
CYP4F2 rs3093105 C vitamin e efficacy no The C allele is not significantly associated with improved liver histology in pediatric or adult patients receiving vitamin E (alpha-tocopherol) supplements. Allele C is not associated with response to vitamin e in people with hepatic steatosis as compared to allele A. 24759732 1184472053
CYP4F2 rs2108622 T warfarin dosage yes Variant described as V433M. This variant was associated with requiring a higher warfarin dose. Alleles have been complemented to the plus chromosomal strand - the T allele represents M. Linear regression and polynomial regression was used to calculate the contribution of each variable towards therapeutic dose of warfarin, prior to the development of pharmacogenetic algorithms. Allele T is associated with increased dose of warfarin. 25084205 1184748929
CYP4F2 rs2108622 T acenocoumarol dosage yes from a GWAS study. Allele T is associated with increased dose of acenocoumarol as compared to allele C. 19578179 1444706936
CYP4F2 rs2108622 CT + TT warfarin dosage no 158/220 patients had the target INR (1.5–2.5). The comparison of weekly warfarin maintenance dose was among patients of different genotypes. Differences in maintenance dose were not observed in patients with variant genotypes of CYP4F2 s2108622. Please note: the alleles are complemented to the + chromosomal strand. Genotypes CT + TT are not associated with dose of warfarin in people with heart valve replacement as compared to genotype CC. 25594941 1444694633
CYP4F2 rs2108622 T warfarin dosage yes The CYP4F2 variant only plays a small effect on warfarin mean weekly dose (MWD). It explained only a further 0.5 % of the MWD variance. Allele T is associated with dose of warfarin as compared to allele C. 26739746 1447680563
CYP4F2 rs2108622 CT + TT warfarin dosage yes only in European Americans, but not African Americans. The dose increase per variant allele was higher among European Americans (5.89% vs 1.23%) compared with African Americans. Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC. 26024874 1445296694
CYP4F2 rs2108622 CT + TT acenocoumarol dosage yes Genotypes CT + TT are associated with increased dose of acenocoumarol as compared to genotype CC. 24956252 1444705851
CYP4F2 rs2108622 C warfarin dosage no CYP4F2 genotype was not associated with stable warfarin dose. Allele C is not associated with dose of warfarin in children as compared to allele T. 24601977 1185235744
CYP4F2 rs2108622 CT + TT acenocoumarol dosage no No significant differences in mean weight normalized acenocoumarol doses were found for these CYP4F2 genotypes. Genotypes CT + TT is not associated with dose of acenocoumarol as compared to genotype CC. 24927344 1444708148
CYP4F2 CYP4F2*1, CYP4F2*3 *3 warfarin dosage yes The authors aimed to develop an admixture-adjusted (genetic ancestry) PGx dosing algorithm for warfarin in Caribbean Hispanics from Puerto Rico. [Algorithm R sq.=0.70, MAE = 0.72 mg/day]. When externally validated with 55 individuals from an independent cohort the novel algorithm predicted 58% of the warfarin dose variance [MAE = 0.89 mg/day, 24% mean bias]. Please note: the derivation cohort was 99% male. CYP4F2 *3 is associated with increased dose of warfarin as compared to CYP4F2 *1. 26745506 1447682700
CYP4F2 rs2108622 TT warfarin dosage yes Patients with the TT genotype had a higher mean warfarin daily dose requirement (3.04+/-0.98 mg/day) as compared to those with the CT (2.66+/-1.02 mg/day, p=0.037) or CC (2.60+/-0.84 mg/day, p=0.034). Additionally, this study developed a pharmacogenetic algorithm to predict daily stable dose of warfarin in Chinese patients; this variant was present in the algorithm. Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation as compared to genotypes CC + CT. 22534826 1448268037
CYP4F2 rs2108622 C warfarin dosage not stated This variant annotation is part of a dosing algorithm table based on 8 genetic variants. Allele C is associated with dose of warfarin as compared to allele T. 27121899 1448109663
CYP4F2 rs2108622 T warfarin dosage not stated This variant was included in an algorithm generated within this study, the WRAPID Dosing Algorithm. Allele T is associated with dose of warfarin. 21725053 1448276458
CYP4F2 rs2108622 T warfarin dosage yes 22 studies with 4,549 were included in the meta-analysis. Most studies were in Chinese patients but 5 were not (2 Japanese, 1 Korean, 1 Indian, 1 Turkish) and one was in a non-specific "Asian" population. Most individuals were prescribed warfarin for heart valve replacement, AF, DVT, pulmonary embolism and stroke. Allele T is associated with increased dose of warfarin as compared to allele C. 27073641 1447983837
CYP4F2 rs2108622 CT + TT warfarin dosage yes in han chinese. Genotypes CT + TT are associated with increased dose of warfarin as compared to genotype CC. 27488389 1448257102
CYP4F2 rs2189784 AG + GG warfarin dosage yes Genotypes AG + GG are associated with increased dose of warfarin in people with heart valve replacement as compared to genotype AA. 28079798 1448567673
CYP4F2 rs2108622 TT warfarin dosage yes Genotype TT is associated with increased dose of warfarin in people with Atrial Fibrillation, heart valve replacement, Hypertension, Pulmonary, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC. 28550460 1448624178
CYP4F2 rs2108622 CC warfarin dosage yes Alleles have been complemented to the positive chromosomal strand. Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotypes CT + TT. 28429387 1448615563
CYP4F2 rs2108622 CC + CT warfarin dosage yes Genotypes CC + CT are associated with decreased dose of warfarin as compared to genotype TT. 28262345 1449005218
CYP4F2 rs2108622 TT warfarin dosage yes Genotype TT is associated with increased dose of warfarin as compared to genotypes CC + CT. 29054760 1449005167
CYP4F2 rs2108622 CT + TT warfarin dosage no Genotypes CT + TT is not associated with increased dose of warfarin in people with Atrial Fibrillation, Cardiomyopathies, heart valve replacement, Peripheral Vascular Diseases, Pulmonary Embolism and Venous Thrombosis as compared to genotype CC. 27938396 1448602262
CYP4F2 rs2108622 T warfarin dosage no There were no significant differences in mean warfarin stable dose (mg/week) (+3 INR stable, no dose change) in the overall group or in the identified "white" subgroup. The self-identified "non-white" subgroup had slight differences in mean warfarin doses (ANOVA p= 0.048 CC = 29.2, CT = 33.1, TT = 33.0). Two self-reported "non-white" patients had the TT genotype. Allele T is not associated with dose of warfarin as compared to allele C. 29875668 1449575733
CYP4F2 rs2108622 T acenocoumarol dosage yes Normalized maintenance dose (NMD): mean maintenance dose/INR at equilibrium). A final multivariate regression model explained 48.1% of the global inter-individual variability in dose requirement. The authors created a clinical algorithm (CA) using patient’s clinical and demographic variables used in the PA. Allele T is associated with increased dose of acenocoumarol in people with Atrial Fibrillation as compared to allele C. 29479633 1449188284
CYP4F2 rs2108622 T acenocoumarol dosage no Allele T is not associated with dose of acenocoumarol or warfarin in people with venous thromboembolism as compared to allele C. 29432897 1449190771
CYP4F2 rs2108622 T warfarin dosage yes Patients were divided into two groups: those who required more than 5 mg/day of warfarin (Group B) and those who required less than 5 mg/day of warfarin (Group A). Within Group B, the frequency of the T allele was 44% vs. 30% in Group A. Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C. 29201113 1449192000
CYP4F2 rs2108622 T warfarin dosage no Allele T is associated with increased dose of warfarin as compared to allele C. 27617219 1449259246
CYP4F2 rs2108622 T warfarin dosage no Allele T is not associated with dose of warfarin as compared to allele C. 28049362 1449251596
CYP4F2 rs2189784 G warfarin dosage no in Alaska Native and American Indian People. Allele G is not associated with dose of warfarin as compared to allele A. 30821933 1450370804
CYP4F2 rs3093153 C warfarin dosage no in Alaska Native and American Indian People. Allele C is not associated with dose of warfarin as compared to allele A. 30821933 1450370821
CYP4F2 CYP4F2*1, CYP4F2*3 *1/*3 + *3/*3 Vitamin K1 metabolism/PK yes Volunteers with the *1/*3 or *3/*3 genotypes had significantly prolonged half-lives of vitamin K1 and significantly increased Cmax and AUC0-24 compared to *1/*1 subjects. *3/*3 volunteers also had a significantly increased AUCinf compared to *1/*1. CYP4F2 *1/*3 + *3/*3 are associated with increased exposure to Vitamin K1 in healthy individuals as compared to CYP4F2 *1/*1. 31134657 1451112060
CYP4F2 rs2108622 T warfarin dosage no Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms. Allele T is not associated with dose of warfarin as compared to allele C. 20128861 1184472389
CYP4F2 rs2108622 CT + TT warfarin dosage yes in the meta-analysis. Carriers of CT, TT genotypes required 10.0% (95% confidence interval(CI) 4.0-15.0) and 21.0% (95% CI 9.0-33.0) higher warfarin doses respectively as compared to the CC genotype (P value <0.05). In addition, T carriers required 11.0% (95% CI 6.0-17.0) higher warfarin dose than CC genotype. Genotypes CT + TT is associated with increased dose of warfarin as compared to genotype CC. 22192158 1184510136
CYP4F2 rs2108622 CT + TT warfarin metabolism/PK yes Those with the CT and TT genotype required a higher median cumulative therapeutic dose of warfarin to reach the target international normalized ratio (INR), as compared to those with the CC genotype. 1% of the variability in dose was attributable to CYP4F2 rs2108622 genotype. Please note alleles have been complemented to the plus chromosomal strand. Genotypes CT + TT is associated with increased dose of warfarin in healthy individuals as compared to genotype CC. 24029542 1184511955
CYP4F2 rs2108622 CC warfarin "dosage","efficacy" yes CC: 3.0 mg/day vs. (CT + TT) : 3.75 mg/day. When the patients were divided into low- and high- dose-requiring subsets based on VKORC1 diplotypes, this association was significant in the low-dose group but not in the high dose group. 18 patients were also taking simvastatin and 19 were also taking omeprazole. Genotype CC is associated with decreased dose of warfarin as compared to genotypes CT + TT. 21084764 981489956
CYP4F2 rs2108622 T Vitamin K metabolism/PK not stated Human Liver Microsomes carrying T had lower vitamin K1 oxidation as well as a decreased steady-state hepatic concentration of Vitamin K1 oxidase. HLM-CC: generated metabolite at 0.85 pmol/min/mg microsomal protein. CT: 0.44 pmol/min/mg; TT: 0.21 pmol/min/mg. Amount of CYP4F2: CC:11.3 pmol/mg microsomal protein; CT:7.2 pmol/mg; TT: 2.5 pmol/mg. Allele T is associated with decreased metabolism of Vitamin K as compared to allele C. 19297519 1183700215
CYP4F2 rs2108622 C warfarin dosage yes Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." rs2108622 was not significantly associated with warfarin maintenance dose in the first cohort but was significant in the multivariate analysis. Allele C is associated with decreased dose of warfarin in people with heart valve replacement as compared to allele T. 25126975 1184756280
CYP4F2 rs2108622 CC + CT aspirin efficacy yes Patients had undergone percutaneous coronary intervention. Cases had definite stent thrombosis during the first 5 days after stent implantation. Controls had no stent thrombosis during the first 30 days following stent implantation. Those with the CT or CC genotype had an increased risk for stent thrombosis as compared to those with the TT genotype. However, this was only significant in multivariate analysis; it was not significant in univariate analysis (p=0.055). Please note alleles have been complemented to the plus chromosomal strand. Genotypes CC + CT is associated with decreased response to aspirin and clopidogrel in people with Acute coronary syndrome as compared to genotype TT. 25712182 1444936362
CYP4F2 rs2108622 CT + TT warfarin dosage no 130 plasma samples were obtained 12 hours after the last dose of warfarin. The plasma warfarin concentrations of these samples were comparing plasma concentration within the group of patients with INR between 1.5–2.5 (n = 92). Please note: alleles have been complemented to the + chromosomal strand. Genotypes CT + TT are not associated with concentrations of warfarin in people with heart valve replacement as compared to genotype CC. 25594941 1444694638
CYP4F2 rs2108622 T warfarin dosage yes The T allele was associated with increased stable dose (mg/day) of warfarin and explained 4.3% of the variance in dose. CC=3.7±0.1 CT=4.3±0.2 TT=5.3±0.4. The addition of rs2108622 to PGx algorithm (included CYP2C9, VKORC1) explained a further 0.5–0.7% of variability. When conditioned on rs7248867, the association w/ rs2108622 & warfarin dose decreased (beta initial = 0.078, beta conditional = 0.065, initial P-value = 0.003, conditional P-value = 0.015). When conditioned on rs2074568, decrease of magnitude and significance also rs2108622 (beta conditional = 0.069, conditional P-value= 0.009). Suggests that rs7248867 and rs2074568 are correlated with rs2108622. Allele T is associated with increased dose of warfarin as compared to allele C. 28620303 1448633907
CYP4F2 rs2108622 T warfarin dosage yes Patients were divided into two groups: those who required more than 5 mg/day of warfarin (Group B) and those who required less than 5 mg/day of warfarin (Group A). Within Group B, the frequency of the T allele was 44% vs. 30% in Group A. Allele T is associated with increased dose of warfarin in people with Cardiovascular Diseases as compared to allele C. 29252193 1449191473
CYP4F2 rs2189784 A warfarin dosage no Neither the addition of race, number of concurrent medications nor the number of concurrent medications interacting with warfarin enhanced algorithm performance. Similarly, consideration of CYP4F2, CALU or GGCX variant genotypes did not improve algorithms. Allele A is not associated with dose of warfarin as compared to allele G. 20128861 1184472404
CYP4F2 rs2108622 T acenocoumarol dosage yes The mean daily dose of individuals with the genotypes CC (N=92), CT (N=88), and TT (N=37) were 3.3 (+/-2.0) mg, 3.1 (+/- 1.6) mg, and 5.3 (+/-3.0) mg. In univariate and multivariate analysis the T allele remained significantly associated with variability in acenocoumarol dose. Please note the alleles have been reported on the + chromosomal strand. The authors report the A allele as being associated with increased dose of acenocoumorol as compared to the G allele. Allele T is associated with increased dose of acenocoumarol as compared to allele C. 25519826 1444699605
CYP4F2 rs2108622 T acenocoumarol dosage not stated This variant was significantly associated with acenocoumarol dose, and explained 3.6% of the variability in dose. Clinical variables (Age, BMI, Enzyme inducers status and Amiodarone status) explained 22% of the variability in dose. This study developed an algorithm for acenocoumarol dosing using clinical and pharmacogenetic data. Allele T is associated with dose of acenocoumarol. 22911785 1448259328
CYP4F2 rs3093105 C warfarin dosage no Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." Allele C is not associated with dose of warfarin in people with heart valve replacement as compared to allele A. 25126975 1184757008
CYP4F2 rs3093158 T warfarin dosage no Samples, genotypes and INRs from a cohort of 551 patients were used to derive an algorithm which was used to predict daily warfarin maintenance dose in a second cohort of 236 patients. Note: the authors state that "SNPs were tested for deviations from HWE using the chi-squared test, and for their association with the warfarin dose by Spearman correlation analysis using a *co-dominant* model." Allele T is not associated with dose of warfarin in people with heart valve replacement as compared to allele C. 25126975 1184757018